Advertisement

Chemistry of Heterocyclic Compounds

, Volume 50, Issue 2, pp 285–286 | Cite as

Reduction of Camphthotecine by 1,4-dihydropyridine

  • A. N. IvchenkoEmail author
  • A. N. Balaev
  • E. A. Ruchko
  • V. E. Fedorov
Article
Topotecan ( 1) is an antitumor drug, whose cytotoxic action is related to the inhibition of DNA topoisomerase I. The key step in the synthesis of topotecan ( 1) is the reduction of camphthotecine ( 2) to give 1,2,6,7-tetrahydrocamphthotecine ( 3) [ 1]. Published variants of this reduction involve the hydrogenation of compound 2 on either platinum or palladium catalysts at atmospheric or elevated pressure [ 2].

Keywords

camphthotecine 1,4-dihydropyridine topotecan reduction 

References

  1. 1.
    W. D. Kingsbury, J. C. Boehm, D. R. Jakas, K. G. Holden, S. M. Hecht, G. Gallagher, M. J. Caranfa, F. L. McCabe, L. F. Faucette, R. K. Johnson, and R. P. Hertzberg, J. Med. Chem., 34, 98 (1991).CrossRefGoogle Scholar
  2. 2.
    S. Sawada, S. Matsuoka, K. Nokata, H. Nagata, T. Furuta, T. Yokokura, and T. Miyasaka, Chem. Pharm. Bull., 39, 3183 (1991).CrossRefGoogle Scholar
  3. 3.
    M. Rueping, C. Azap, E. Sugiono, and T. Theissmann, Synlett, 2367 (2005).Google Scholar
  4. 4.
    M. Rueping, T. Theissmann, and A. P. Antonchick, Synlett, 1071 (2006).Google Scholar
  5. 5.
    G.-W. Wang, J.-J. Xia, C.-B. Miao, and X.-L. Wu, Bull. Soc. Chem. Japan, 79, 454 (2006).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • A. N. Ivchenko
    • 1
    Email author
  • A. N. Balaev
    • 1
  • E. A. Ruchko
    • 1
  • V. E. Fedorov
    • 1
  1. 1.Pharm SintezMoscowRussia

Personalised recommendations